Skip to main content

Table 2 Progression-free survival in locally advanced rectal cancer

From: Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer

  HR1 95 % CI p-value
ΔNACT   0.994 (0.990–0.999) 0.01
Age   0.953 (0.914–0.993) 0.02
TN stage T2–3    
T4 2.71 (1.17–6.27) 0.02
  N0–1    
N2 1.22 (0.449–3.30) 0.70
Baseline CEA level ≤ULN    
>ULN 1.85 (0.799–4.29) 0.15
ypTN ypT0–2    
ypT3–4 6.10 (2.22–16.7) <0.001
  ypN0    
ypN1–2 2.84 (1.20–6.70) 0.02
TRG score TRG1–2    
TRG3–5 3.00 (1.27–7.08) 0.01
  1. Adjusted hazard ratio (HR) with 95 % confidence interval (CI) was calculated by univariate Cox regression analysis for each of the indicated variables
  2. ΔNACT paired serum sample measurements of carbonic anhydrase IX following neoadjuvant induction chemotherapy versus baseline, CEA carcinoembryonic antigen, ULN upper limit of normal, TRG tumour regression grade
  3. 1: HR less than 1 indicates that patients had higher probability of favourable progression-free survival